Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-glycosyl isoquercitrin (AGIQ) is a highly bioavailable derivative of quercetin, a flavonoid well-known for its antioxidant and anti-inflammatory properties. The use of AGIQ in supporting or treating Inflammatory Bowel Disorders (IBD) has some basis in scientific literature, though the evidence is preliminary and primarily limited to in vitro and animal studies, rather than large-scale human clinical trials.

Preclinical studies suggest that AGIQ, like quercetin, can inhibit pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) and modulate signaling pathways (notably NF-κB), both of which are implicated in the pathogenesis of IBD. In rodent models of colitis, AGIQ has demonstrated protective effects against intestinal inflammation, likely due to its antioxidant capacity and ability to stabilize mast cells and reduce oxidative stress within the gut mucosa. Furthermore, AGIQ’s enhanced water solubility and absorption over standard quercetin make it a promising candidate for oral supplementation.

However, human studies specific to AGIQ in IBD are lacking. While quercetin itself has shown some benefit in preliminary clinical trials for ulcerative colitis, direct evidence for AGIQ is sparse. Thus, while there is a scientific rationale and some supportive evidence from animal studies, robust clinical validation in humans is currently insufficient.

In summary, AGIQ is supported by early scientific research for potential use in IBD, but its use is not yet strongly validated and should be considered experimental pending further human trials.

More about alpha-glycosyl isoquercitrin
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by alpha-glycosyl isoquercitrin

Products containing alpha-glycosyl isoquercitrin